ProChon Biotech Ltd. Selects Averion International Corp. for the BioCart(TM) Cartilage Regeneration System Study

WOBURN, Mass.--(BUSINESS WIRE)--ProChon Biotech, Ltd., an innovator of tissue regenerative technologies that are being developed to relieve pain and restore the mobility and quality of life for sufferers of articular cartilage injuries, today announced that it has selected Averion International Corp. (OTC BB: AVRO), a leading international clinical research organization, to support and manage the clinical development of ProChon’s BioCart™ Autologous Cartilage Regeneration System.

Back to news